Manufacturer:
Merck
Route of Administration:
Oral
Site of Care:
Outpatient
Website:
Approved Indication:
treatment of adults with chronic HCV genotype 1 or 4 infection without cirrhosis or with compensated cirrhosis in combination with ribavirin for certain patient populations
Conditions:
- Chronic Viral Hepatitis C
Therapeutic Area:
- Gastroenterology
- Infectious Disease
- Hepatology